Cargando…

356. Impact of CLSI Breakpoint Changes on Unit-Specific Combination Antibiograms for Gram-Negative Respiratory Isolates

BACKGROUND: In 2023, the CLSI updated aminoglycoside breakpoints for P. aeruginosa and Enterobacterales. The anticipated decrease in aminoglycoside susceptibility rates resulting from these revised breakpoints will impact empiric antibiotic selection for nosocomial pneumonia. This study aims to eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wangchinda, Walaiporn, Aitken, Samuel L, Pierce, Virginia M, Lephart, Paul, Pogue, jason M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678067/ http://dx.doi.org/10.1093/ofid/ofad500.427

Ejemplares similares

355. Stratification of Patient-Specific Risk Factors for Multidrug-Resistant Gram-Negative Respiratory Pathogens in Intensive Care Units (ICU)
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

354. A Comparison of Different Strategies for Optimizing the Selection of Empiric Antibiotic Therapy for Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) Caused by Gram-Negative Bacteria in Intensive Care Units (ICU)
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

976. Population Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analysis of Intravenous Fosfomycin for Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

230. Multicenter Assessment of the Accuracy of MIC Results for Colistin with MicroScan Dried Gram Negative MIC Panels using CLSI Breakpoints
por: Riedel, Stefan, et al.
Publicado: (2022)

667. Multicenter Assessment of Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa Using Updated CLSI Levofloxacin Breakpoints on MicroScan Dried Gram Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2020)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

642. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

722. Risk Factors for Infection or Colonization with Ceftolozane/Tazobactam Non-Susceptible Extensively β-Lactam Resistant Pseudomonas aeruginosa
por: Lee, Michelle, et al.
Publicado: (2023)

673. Updated CLSI Ciprofloxacin Breakpoints from a Multicenter Assessment for Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa Using MicroScan Dried Gram Negative MIC Panels
por: Traczewski, Maria M, et al.
Publicado: (2020)

786. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) From 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms
por: Wolfensberger, Aline, et al.
Publicado: (2013)

Gram-Negative Polymicrobial Bloodstream Infections and Clinical Decision Making with a Microarray Testing System
por: Claeys, Kimberly, et al.
Publicado: (2017)

1253. Optimization of empiric gram-negative infections with the combination antibiogram
por: Leung, Anthony K, et al.
Publicado: (2023)

CLSI based antibiogram profile and the detection of MDR and XDR strains of Acinetobacter baumannii isolated from urine samples
por: Girija AS, Smiline, et al.
Publicado: (2019)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Impact of CLSI Break Point Changes Over the Past Decade on Antimicrobial Susceptibility in Gram-Negative Bacteria
por: Johnson, Wesley, et al.
Publicado: (2021)

1181. Use of the Combination Antibiogram in the Era of MDR Gram-Negative Pathogens
por: Klinker, Kenneth, et al.
Publicado: (2018)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

CLSI announces availability of new CLSI microbiology documents
Publicado: (2007)

Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
por: O’Donnell, J Nicholas, et al.
Publicado: (2017)

Changing times: The impact of gram-negative breakpoint changes over the previous decade
por: Johnson, Wes M., et al.
Publicado: (2022)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision
por: Wang, Ying, et al.
Publicado: (2021)

2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

647. Adoption of the updated fluoroquinolones breakpoints for Gram negative bacteria in clinical microbiology laboratories
por: Sfeir, Maroun M
Publicado: (2020)

Antibiogram and Genetic Characterization of Carbapenem-Resistant Gram-Negative Pathogens Incriminated in Healthcare-Associated Infections
por: Makharita, Rabab R, et al.
Publicado: (2020)

Inhibition and Reduction of Biofilm Production along with Their Antibiogram Pattern among Gram-Negative Clinical Isolates
por: Shrestha, Ojaswee, et al.
Publicado: (2023)

Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates
por: Shealy, Stephanie C., et al.
Publicado: (2020)

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
por: Lee, Ching-Chi, et al.
Publicado: (2019)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

1597. Evaluation of Ceftaroline Resistance (CPT-R) in Chile Across Time and a Comparison of CLSI vs. EUCAST Breakpoints in Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Khan, Ayesha, et al.
Publicado: (2019)

‘Breakpoint broth microdilution plate’ for susceptibility testing of Gram negative bacilli against colistin sulfate
por: Ahmed, Imran, et al.
Publicado: (2020)

Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement
por: Gaur, Priyanka, et al.
Publicado: (2023)

The metabolic regimes of 356 rivers in the United States
por: Appling, Alison P., et al.
Publicado: (2018)

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
por: Wu, Janet Y., et al.
Publicado: (2020)

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints
por: Kuti, Joseph L, et al.
Publicado: (2018)

2144. Performance of 2019 CLSI Ciprofloxacin Breakpoint Antimicrobial Susceptibility Testing Algorithms for Enterobacteriaceae and Pseudomonas aeruginosa Directly from Positive Blood Culture on the Accelerate Pheno™ System
por: Shamsheyeva, Alena, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens
por: Bian, Xingchen, et al.
Publicado: (2022)

Susceptibility of Dermatophytes to Thiabendazole Using CLSI Broth Macrodilution
por: Robledo-Leal, Efrén, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8gttlsufvqrn8rkpd7449flm2k